期刊
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
卷 12, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1758835920927850
关键词
cancer; drug resistance; EMT; long noncoding RNAs; mechanisms
类别
资金
- National Key Research and Development Program of China [2018YFE0107800]
- Jilin University [SXGJSF2017-1]
- Jilin Province in China [SXGJSF2017-1]
- Research Grant Council, HKSAR [RGC GRF 17152116]
- Commissioner for Innovation Technology, HKSAR [ITS/091/16FX]
- Health and Medical Research Fund [15162961]
Chemotherapy is one of the fundamental methods of cancer treatment. However, drug resistance remains the main cause of clinical treatment failure. We comprehensively review the newly identified roles of long noncoding RNAs (lncRNAs) in oncobiology that are associated with drug resistance. The expression of lncRNAs is tissue-specific and often dysregulated in human cancers. Accumulating evidence suggests that lncRNAs are involved in chemoresistance of cancer cells. The main lncRNA-driven mechanisms of chemoresistance include regulation of drug efflux, DNA damage repair, cell cycle, apoptosis, epithelial-mesenchymal transition (EMT), induction of signaling pathways, and angiogenesis. LncRNA-driven mechanisms of resistance to various antineoplastic agents have been studied extensively. There are unique mechanisms of resistance against different types of drugs, and each mechanism may have more than one contributing factor. We summarize the emerging strategies that can be used to overcome the technical challenges in studying and addressing lncRNA-mediated drug resistance.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据